side effects of glp-1 drugs Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity Struggling with GLP-1 therapy side

These medications work by mimicking natural hormones that regulate blood sugar and appetite, leading to improved glycemic control and significant weight loss in many patients

Research published in The Lancet examining GLP-1 receptor agonist eligibility across 99 countries found that eligibility varies dramatically based on which BMI thresholds are used

GLP-1 acts through its receptors, GLP-1R, which is expressed in different tissues, including the pancreas, heart, kidney, adipose, and central nervous system

Our study showed no differences for VitD and OCN at baseline between those with osteoporosis and without osteoporosis at follow-up

This was predominantly driven by the continuing roll-out of Novo Nordisks semaglutide and Lillys tirzepatide, and off-label use of their respective T2D-indicated brands

The primary outcome was gestational weight gain, calculated as the difference between the last recorded weight within 1 week of delivery and prepregnancy weight